ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival.
Open access · greenAbstract read
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Risk-based breast cancer screening.British journal of cancer · 2026Article
- Polygenic risk score and 20-year prostate cancer-specific mortality and survival.Communications medicine · 2026Article
- Decoding clone evolution in HER2 amplified breast cancer through single-cell and spatial transcriptomics analysis of copy number variations.Scientific reports · 2026Article
- Breast cancer risk level and prediction of tumor aggressiveness in the Athena Breast Health Network.Breast cancer research and treatment · 2026Article
- MGAT4EP promotes tumor progression and serves as a prognostic marker for breast cancer.Cancer biology & therapy · 2025Article
- Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Bioinformatics analysis of IFI6 as a novel prognostic biomarker and its correlation with immune infiltration in breast cancer.Scientific reports · 2025Article
- Article
- Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast Cancer.Geburtshilfe und Frauenheilkunde · 2025Article
- Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.Breast cancer research and treatment · 2025Review
- Clinical genetics in breast cancer.Journal of surgical oncology · 2024Review
- Article
- DNA methylation at quantitative trait loci (mQTLs) varies with cell type and nonheritable factors and may improve breast cancer risk assessment.NPJ precision oncology · 2023Article
- An apparent quandary: adoption of polygenics and gene panels for personalised breast cancer risk stratification.BJC reports · 2023Review
- Update Breast Cancer 2023 Part 1 - Early Stage Breast Cancer.Geburtshilfe und Frauenheilkunde · 2023Article
- Development and testing of a polygenic risk score for breast cancer aggressiveness.NPJ precision oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 12 institutions in 9 countries.
Josephine M N Lopes CardozoDepartment of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.ORCID 0000-0003-0520-0282
Irene L AndrulisFred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada.ORCID 0000-0002-4226-6435
Stig E BojesenCopenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.ORCID 0000-0002-4061-4133
Thilo DörkGynaecology Research Unit, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-9458-0282
Diana M EcclesFaculty of Medicine, University of Southampton, Southampton, United Kingdom.ORCID 0000-0002-9935-3169
Peter A FaschingDepartment of Gynecology and Obstetricss, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0003-4885-8471
Maartje J HooningDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.ORCID 0000-0001-6763-0857
Renske KeemanDivision of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0002-5452-9933
Heli NevanlinnaDepartment of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Emiel J T RutgersDepartment of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.ORCID 0000-0002-4244-0106
Douglas F EastonCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-2444-3247
Per HallDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-5640-9126
Paul D P PharoahCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
Laura J van 't VeerUCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-9838-8298
Marjanka K SchmidtDivision of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0002-2228-429X
Breast Cancer Association Consortium and MINDACT Collaborators
The Netherlands Cancer Institute · NLUniversitätsklinikum Erlangen · DELeiden University Medical Center · NLUniversity of California, San Francisco · USUniversity of Cambridge · GBUniversity of Southampton · GBErasmus MC Cancer Institute · NLKarolinska Institutet · SEMedizinische Hochschule Hannover · DEMount Sinai Hospital · CAUniversity of Copenhagen · DKUniversity of Helsinki · FI
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8MVIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9MTransgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3MStatistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8MSouthern Community Cohort StudyR01CA092447 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLOT, WILLIAM J., ZHENG, WEI · 2001 to 2015
$74.0MTissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHARLES M PEROU · 1992 to 2026
$59.3MThe Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI Fergus Joseph Couch · 2005 to 2026
$49.9MUnderstanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4MUNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3MCALIFORNIA TEACHERS STUDYR01CA077398 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BERNSTEIN, LESLIE · 1998 to 2014
$29.7MGENETIC SUSCEPTIBILITY TO CANCER IN MULTIETHNIC COHORTSR01CA063464 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2001 to 2005
$23.2MMultiethnic Cohort Study of Diet and CancerR37CA054281 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI KOLONEL, LAURENCE N. · 2003 to 2012
$23.2MCancer Research UK C12292/A11174Cancer Research UK C1281/A12014Cancer Research UK C1287/A10118Cancer Research UK C1287/A10710Cancer Research UK C1287/A16563Cancer Research UK C5047/A10692Cancer Research UK C5047/A15007Cancer Research UK C5047/A8384Cancer Research UK C570/A16491Cancer Research UK C8197/A16565Cancer Research UK C8221/A19170Intramural NIH HHS Z01 CP010119Intramural NIH HHS Z01 ES049030Medical Research Council G1000143Medical Research Council MR/M012190/1NCCDPHP CDC HHS NU58DP006344NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800016CNCI NIH HHS HHSN261201800016INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032INCI NIH HHS K07 CA092044NCI NIH HHS K12 CA090628NCI NIH HHS K24 CA169004NCI NIH HHS N01 CN025403NCI NIH HHS P01 CA087969NCI NIH HHS P30 CA023100NCI NIH HHS P30 CA033572NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA058223NCI NIH HHS P50 CA116201NCI NIH HHS R01 CA054281NCI NIH HHS R01 CA058860NCI NIH HHS R01 CA063464NCI NIH HHS R01 CA064277NCI NIH HHS R01 CA077398NCI NIH HHS R01 CA092447NCI NIH HHS R01 CA097396NCI NIH HHS R01 CA100374NCI NIH HHS R01 CA116167NCI NIH HHS R01 CA120120NCI NIH HHS R01 CA128931NCI NIH HHS R01 CA128978NCI NIH HHS R01 CA132839NCI NIH HHS R01 CA140286NCI NIH HHS R01 CA148667NCI NIH HHS R01 CA163353NCI NIH HHS R01 CA176785NCI NIH HHS R01 CA177150NCI NIH HHS R01 CA192393NCI NIH HHS R03 CA130065NCI NIH HHS R35 CA253187NCI NIH HHS R37 CA054281NCI NIH HHS R37 CA070867NCI NIH HHS U01 CA058860NCI NIH HHS U01 CA063464NCI NIH HHS U01 CA098758NCI NIH HHS U01 CA164920NCI NIH HHS U01 CA164973NCI NIH HHS U01 CA176726NCI NIH HHS U01 CA179715NCI NIH HHS U01 CA199277NCI NIH HHS U19 CA148065NCI NIH HHS U19 CA148112NCI NIH HHS U19 CA148537NCI NIH HHS U54 CA156733NCI NIH HHS UM1 CA164917NCI NIH HHS UM1 CA164920NCI NIH HHS UM1 CA164973NCI NIH HHS UM1 CA176726NCI NIH HHS UM1 CA186107NHLBI NIH HHS HHSN268201100001INHLBI NIH HHS HHSN268201100002INHLBI NIH HHS HHSN268201100003INHLBI NIH HHS HHSN268201100004INHLBI NIH HHS HHSN268201100046CNIA NIH HHS HHSN271201100004CNIEHS NIH HHS P30 ES010126Wellcome Trust 203477/Z/16/ZWHI NIH HHS HHSN268201100001CWHI NIH HHS HHSN268201100002CWHI NIH HHS HHSN268201100003CWHI NIH HHS HHSN268201100004C
Abstract
purposeA polygenic risk score (PRS) consisting of 313 common genetic variants (PRS
methodsWomen with invasive breast cancer were included, 98,397 of European ancestry and 12,920 of Asian ancestry, from the Breast Cancer Association Consortium (BCAC), and 683 women from the European MINDACT trial. Associations between PRS
resultsThe PRS
conclusionAn increased PRS
Indexed as
Breast NeoplasmsBreastFemaleHumansPrognosisProportional Hazards ModelsRisk Factors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.